REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests

FDA is unwilling to subject organ transplant patients to the delays caused by requiring prescriber and pharmacy certification, and so the REMS requirements for mycophenolate products are less strict than for other, less critical teratogenic drugs.